Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand

  • Crichton, S.
  • Belfrage, E.
  • Collins, I.J.
  • Doerholt, K.
  • Judd, A.
  • Le Coeur, S.
  • Spoulou, V.
  • Goodall, R.
  • Scherpbier, H.
  • Smit, C.
  • Goetghebuer, T.
  • Gibb, D.M.
  • Noguera, A.
  • Navarro, M.L.
  • Ramos, J.T.
  • Galli, L.
  • Giaquinto, C.
  • Thorne, C.
  • Santa Ansone.
  • Marczynska, M.
  • Okhonskaia, L.
  • de Tejada, BM.
  • Jourdain, G.
  • Decker, L.
  • Ene, L.
  • Hainaut, M.
  • Van der Kelen, E.
  • Delforge, M.
  • de Martino, M.
  • Tovo, PA.
  • Patrizia, O.
  • Larovere, D.
  • Ruggeri, M.
  • Faldella, G.
  • Baldi, F.
  • Badolato, R.
  • Montagnani, C.
  • Venturini, E.
  • Lisi, C.
  • Di Biagio, A.
  • Taramasso, L.
  • Giacomet, V.
  • Erba, P.
  • Esposito, S.
  • Lipreri, R.
  • Salvini, F.
  • Tagliabue, C.
  • Cellini, M.
  • Bruzzese, E.
  • Lo Vecchio, A.
  • Rampon, O.
  • Dona, D.
  • Romano, A.
  • Dodi, I.
  • Maccabruni, A.
  • Consolini, R.
  • Bernardi, S.
  • Kuekou, HT.
  • Genovese, O.
  • Olmeo, P.
  • Cristiano, L.
  • Mazza, A.
  • Gabiano, C.
  • Garazzino, S.
  • Pellegatta, A.
  • Pajkrt, D.
  • Scherpbier, HJ.
  • Weijsenfeld, AM.
  • de Boer, CG.
  • Jurriaans, S.
  • Back, NKT.
  • Zaaijer, HL.
  • Berkhout, B.
  • Cornelissen, MTE.
  • Schinkel, CJ.
  • Wolthers, KC.
  • Fraaij, PLA.
  • van Rossum, AMC.
  • Vermont, CL.
  • van der Knaap, LC.
  • Visser, EG.
  • Boucher, CAB.
  • Koopmans, MPG.
  • van Kampen, JJA.
  • Pas, SD.
  • Henriet, SSV.
  • van de Flier, M.
  • van Aerde, K.
  • Strik-Albers, R.
  • Rahamat-Langendoen, J.
  • Stelma, FF.
  • Scholvinck, EH.
  • de Groot-de Jonge, H.
  • Niesters, HGM.
  • van Leer-Buter, CC.
  • Knoester, M.
  • Bont, LJ.
  • Geelen, SPM.
  • Wolfs, TFW.
  • Nauta, N.
  • Schuurman, R.
  • Verduyn-Lunel, F.
  • Wensing, AMJ.
  • Reiss, P.
  • Zaheri, S.
  • Bezemer, DO.
  • van Sighem, AI.
  • Smit, C.
  • Wit, FWMN.
  • Hillebregt, M.
  • de Jong, A.
  • Woudstra, T.
  • Bergsma, D.
  • Grivell, S.
  • Meijering, R.
  • Raethke, M.
  • Rutkens, T.
  • de Groot, L.
  • van den Akker, M.
  • Bakker, Y.
  • Bezemer, M.
  • El Berkaoui, A.
  • Geerlinks, J.
  • Koops, J.
  • Kruijne, E.
  • Lodewijk, C.
  • Lucas, E.
  • van der Meer, R.
  • Munjishvili, L.
  • Paling, E.
  • Peeck, B.
  • Ree, C.
  • Regtop, R.
  • Ruijs, Y.
  • van de Sande, L.
  • Schoorl, M.
  • Schnorr, P.
  • Tuijn, E.
  • Veenenberg, L.
  • van der Vliet, S.
  • Wisse, A.
  • Witte, EC.
  • Tuk, B.
  • Popielska, J.
  • Pokorska-Spiewak, M.
  • Oldakowska, A.
  • Zawadka, K.
  • Coupland, U.
  • Doroba, M.
  • Voronin, E.
  • Miloenko, M.
  • Labutina, S.
  • Soler-Palacin, P.
  • Frick, MA.
  • Perez-Hoyos, S.
  • Mur, A.
  • Lopez, N.
  • Mendez, M.
  • Mayol, L.
  • Vallmanya, T.
  • Calavia, O.
  • Garcia, L.
  • Coll, M.
  • Pineda, V.
  • Rius, N.
  • Rovira, N.
  • Duenas, J.
  • Gamell, A.
  • Fortuny, C.
  • Noguera-Julian, A.
  • Mellado, MJ.
  • Escosa, L.
  • Hortelano, MG.
  • Sainz, T.
  • Gonzalez-Tome, MI.
  • Rojo, P.
  • Blazquez, D.
  • Prieto, L.
  • Guillen, S.
  • Saavedra, J.
  • Santos, M.
  • Munoz, MA.
  • Ruiz, B.
  • Mc Phee, CF.
  • de Ory, SJ.
  • Alvarez, S.
  • Roa, MA.
  • Beceiro, J.
  • Martinez, J.
  • Badillo, K.
  • Apilanez, M.
  • Pocheville, I.
  • Garrote, E.
  • Colino, E.
  • Sirvent, JG.
  • Garzon, M.
  • Roman, V.
  • Montesdeoca, A.
  • Mateo, M.
  • Munoz, MJ.
  • Angulo, R.
  • Neth, O.
  • Falcon, L.
  • Terol, P.
  • Santos, JL.
  • Moreno, D.
  • Lendinez, F.
  • Grande, A.
  • Romero, FJ.
  • Perez, C.
  • Lillo, M.
  • Losada, B.
  • Herranz, M.
  • Bustillo, M.
  • Guerrero, C.
  • Collado, P.
  • Couceiro, JA.
  • Perez, A.
Objective: The aim of this study was to describe growth during puberty in young people with vertically acquired HIV. Design: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand. Methods: One thousand and ninety-four children initiating a nonnucleoside reverse transcriptase inhibitor or boosted protease inhibitor based regimen aged 1-10 years were included. Super Imposition by Translation And Rotation (SITAR) models described growth from age 8 years using three parameters (average height, timing and shape of the growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics associated with these three parameters. Results: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8, 9.0] years and -1.2 (IQR: -2.3 to -0.2), respectively. Median follow-up was 9.1 (IQR: 6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20-0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years and 1.50 (1.21-1.78) years later in those starting with HAZ less than -3 compared with HAZ at least -1. Later growth spurts in girls resulted in continued height growth into later adolescence. In boys starting ART with HAZ less than -1, growth spurts were later in children starting ART in the oldest age group, but for HAZ at least -1, there was no association with age. Girls and boys who initiated ART with HAZ at least -1 maintained a similar height to the WHO reference mean. Conclusion: Stunting at ART initiation was associated with later growth spurts in girls. Children with HAZ at least -1 at ART initiation grew in height at the level expected in HIV negative children of a comparable age.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Interruptions of antiretroviral therapy in human immunodeficiency virus infection, are they detrimental to neurocognitive functioning?

  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Fumaz, Carmina R.|||0000-0003-0838-3395
  • Prats, Anna|||0000-0002-3586-4525
  • Ferrer, Maria Jose
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Moltó, José|||0000-0003-4564-1963
  • Gómez Melis, Guadalupe|||0000-0003-4252-4884
  • Garolera Freixa, Maite|||0000-0001-7443-8249
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
Background: Since interruptions of antiretroviral treatment may entail clinical risks for HIV-infected individuals, we investigated their impact on neurocognitive functioning. Methods: Cross-sectional study comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (non-interruption group, NIG). Interruption was defined as the discontinuation of HAART for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. Results: A total of 83 subjects participated in the study (IG: n=27, NIG: n=56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13.8; NIG, 10.2 [p=0.003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59.25%; NIG, 33.92% [p=0.02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. Conclusions: In our study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mechanisms of abrupt loss of virus control in a cohort of previous HIV controllers

  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Bellido, Rocío
  • Olvera, Alex|||0000-0002-9934-5759
  • Ruiz Riol, Marta|||0000-0003-1899-8879
  • Rocafort, Muntsa|||0000-0002-2991-1444
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Cobarsi, Patricia|||0000-0003-3977-230X
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Dorrell, Lucy
  • Del Romero, Jorge
  • Alcami, Jose|||0000-0003-0023-7377
  • Paredes, Roger|||0000-0002-6553-691X
  • Brander, Christian|||0000-0002-0548-5778
  • Mothe, Beatriz|||0000-0001-9975-407X
A few individuals can control HIV infection without the need for antiretroviral treatment and are referred to as HIV controllers. We have studied HIV controllers who suddenly lose this ability and present with high in vivo viral replication and decays in their CD4 + T-cell counts to identify potential immune and virological factors that were responsible for initial virus control. We identify in vitro -determined reductions in the ability of CD8 T cells to suppress viral control and the presence of PD-1-expressing CD8 + T cells with a naive immune phenotype as potential predictors of in vivo loss of virus control. The findings could be important for the clinical management of HIV controller individuals, and it may offer an important tool to anticipate viral rebound in individuals in clinical studies that include combination antiretroviral therapy (cART) treatment interruptions and which, if not treated quickly, could pose a significant risk to the trial participants. Elite and viremic HIV controllers are able to control their HIV infection and maintain undetectable or low-level viremia in the absence of antiretroviral treatment. Despite extensive studies, the immune factors responsible for such exclusive control remain poorly defined. We identified a cohort of 14 HIV controllers that suffered an abrupt loss of HIV control (LoC) to investigate possible mechanisms and virological and immunological events related to the sudden loss of control. The in-depth analysis of these subjects involved the study of cell tropism of circulating virus, evidence for HIV superinfection, cellular immune responses to HIV, as well as an examination of viral adaptation to host immunity by Gag sequencing. Our data demonstrate that a poor capacity of T cells to mediate in vitro viral suppression, even in the context of protective HLA alleles, predicts a loss of viral control. In addition, the data suggest that inefficient viral control may be explained by an increase of CD8 T-cell activation and exhaustion before LoC. Furthermore, we detected a switch from C5- to X4-tropic viruses in 4 individuals after loss of control, suggesting that tropism shift might also contribute to disease progression in HIV controllers. The significantly reduced inhibition of in vitro viral replication and increased expression of activation and exhaustion markers preceding the abrupt loss of viral control may help identify untreated HIV controllers that are at risk of losing control and may offer a useful tool for monitoring individuals during treatment interruption phases in therapeutic vaccine trials. IMPORTANCE A few individuals can control HIV infection without the need for antiretroviral treatment and are referred to as HIV controllers. We have studied HIV controllers who suddenly lose this ability and present with high in vivo viral replication and decays in their CD4 + T-cell counts to identify potential immune and virological factors that were responsible for initial virus control. We identify in vitro -determined reductions in the ability of CD8 T cells to suppress viral control and the presence of PD-1-expressing CD8 + T cells with a naive immune phenotype as potential predictors of in vivo loss of virus control. The findings could be important for the clinical management of HIV controller individuals, and it may offer an important tool to anticipate viral rebound in individuals in clinical studies that include combination antiretroviral therapy (cART) treatment interruptions and which, if not treated quickly, could pose a significant risk to the trial participants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study

  • Echeverría, Patricia|||0000-0003-2755-3695
  • Bonjoch, Anna|||0000-0002-5343-2881
  • Puig, Jordi|||0000-0002-4075-0346
  • Moltó, José|||0000-0003-4564-1963
  • Paredes, Roger|||0000-0002-6553-691X
  • Sirera, Guillem|||0000-0003-4014-9355
  • Ornelas, Arelly
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has also shown antiviral efficacy in antiretroviral-naïve patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking. HIV-1-infected patients with suppressed viral load (VL) during a PI-containing regimen (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study

  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Gallego-Escuredo, José Miguel
  • Torres, Ferran|||0000-0002-7355-7913
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Villarroya, Joan
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Rio, Luis del
  • Estrada, Vicente|||0000-0002-7795-5986
  • Girlat, Marta|||0000-0001-7968-4190
HIV-1/HAART-associated lipodystrophy syndrome (HALS) has been associated with exposure to stavudine (d4T) through mitochondrial dysfunction. We performed a 48-week study to assess the effects of switching from d4T to raltegravir (RAL) on metabolic and fat molecular parameters of patients with HALS. Forty-two patients with HALS and a median exposure to d4T.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice, Results from a Mediterranean Cohort of HIV-Infected Patients

  • Echeverría, Patricia|||0000-0003-2755-3695
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Llibre Codina, Josep Maria|||0000-0002-7158-6753
  • Gutierrez, Mª del Mar|||0000-0002-0691-1206
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Puig, Jordi|||0000-0002-4075-0346
  • Bonjoch, Anna|||0000-0002-5343-2881
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Sirera, Guillem|||0000-0003-4014-9355
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
Background. There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable cardiovascular risk factors (CVRF) in HIV-infected patients. Methods. We performed a retrospective descriptive study to determine the prevalence of coronary events and to evaluate the management of CVRF in a Mediterranean cohort of 3760 HIV-1-infected patients from April 1983 through June 2011. Results. We identified 81 patients with a history of a coronary event (prevalence 2.15%); 83% of them suffered an acute myocardial infarction. At the time of the coronary event, CVRF were highly prevalent (60.5% hypertension, 48% dyslipidemia, and 16% diabetes mellitus). Other CVRF, such as smoking, hypertension, lack of exercise, and body mass index, were not routinely assessed. After the coronary event, a significant decrease in total cholesterol (P = 0.025) and LDL-cholesterol (P = 0.004) was observed. However, the percentage of patients who maintained LDL-cholesterol.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional Analyses Reveal Extensive RRE Plasticity in Primary HIV-1 Sequences Selected under Selective Pressure

  • Cunyat, Francesc|||0000-0002-1284-6324
  • Beerens, Nancy
  • García Rodríguez, Elisabet
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Kjems, Jørgen
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
HIV-1 Rev response element (RRE) is a functional region of viral RNA lying immediately downstream to the junction of gp120 and gp41 in the env coding sequence. The RRE is essential for HIV replication and binds with the Rev protein to facilitate the export of viral mRNA from nucleus to cytoplasm. It has been suggested that changes in the predicted secondary structure of primary RRE sequences impact the function of the RREs; however, functional assays have not yet been performed. The aim of this study was to characterize the genetic, structural and functional variation in the RRE primary sequences selected in vivo by Enfuvirtide pressure. Multiple RRE variants were obtained from viruses isolated from patients who failed an Enfuvirtide-containing regimen. Different alterations were observed in the predicted RRE secondary structures, with the abrogation of the primary Rev binding site in one of the variants. In spite of this, most of the RRE variants were able to bind Rev and promote the cytoplasmic export of the viral mRNAs with equivalent efficiency in a cell-based assay. Only RRE45 and RRE40-45 showed an impaired ability to bind Rev in a gel-shift binding assay. Unexpectedly, this impairment was not reflected in functional capacity when RNA export was evaluated using a reporter assay, or during virus replication in lymphoid cells, suggesting that in vivo the RRE would be highly malleable. The Rev-RRE functionality is unaffected in RRE variants selected in patients failing an ENF-containing regimen. Our data show that the current understanding of the Rev-RRE complex structure does not suffice and fails to rationally predict the function of naturally occurring RRE mutants. Therefore, this data should be taken into account in the development of antiviral agents that target the RRE-Rev complex.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA, Diagnostic Accuracy, Viral Evolution and Compartmentalization

  • Pou, Christian|||0000-0003-3932-788X
  • Codoñer, Francisco M.
  • Thielen, Alexander
  • Bellido, Rocío
  • Pérez-Álvarez, Susana
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • Dalmau, Judith|||0000-0001-7513-3711
  • Curriu Martí, Marta
  • Lie, Yolanda
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Puig, Jordi|||0000-0002-4075-0346
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Blanco, Julià|||0000-0002-2225-0217
  • Coakley, Eoin
  • Däumer, Martin
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Paredes, Roger|||0000-0002-6553-691X
Technically, HIV-1 tropism can be evaluated in plasma or peripheral blood mononuclear cells (PBMCs). However, only tropism testing of plasma HIV-1 has been validated as a tool to predict virological response to CCR5 antagonists in clinical trials. The preferable tropism testing strategy in subjects with undetectable HIV-1 viremia, in whom plasma tropism testing is not feasible, remains uncertain. We designed a proof-of-concept study including 30 chronically HIV-1-infected individuals who achieved HIV-1 RNA <50 copies/mL during at least 2 years after first-line ART initiation. First, we determined the diagnostic accuracy of 454 and population sequencing of gp120 V3-loops in plasma and PBMCs, as well as of MT-2 assays before ART initiation. The Enhanced Sensitivity Trofile Assay (ESTA) was used as the technical reference standard. 454 sequencing of plasma viruses provided the highest agreement with ESTA. The accuracy of 454 sequencing decreased in PBMCs due to reduced specificity. Population sequencing in plasma and PBMCs was slightly less accurate than plasma 454 sequencing, being less sensitive but more specific. MT-2 assays had low sensitivity but 100% specificity. Then, we used optimized 454 sequence data to investigate viral evolution in PBMCs during viremia suppression and only found evolution of R5 viruses in one subject. No de novo CXCR4-using HIV-1 production was observed over time. Finally, Slatkin-Maddison tests suggested that plasma and cell-associated V3 forms were sometimes compartmentalized. The absence of tropism shifts during viremia suppression suggests that, when available, testing of stored plasma samples is generally safe and informative, provided that HIV-1 suppression is maintained. Tropism testing in PBMCs may not necessarily produce equivalent biological results to plasma, because the structure of viral populations and the diagnostic performance of tropism assays may sometimes vary between compartments. Thereby, proviral DNA tropism testing should be specifically validated in clinical trials before it can be applied to routine clinical decision-making.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function

  • Curriu Martí, Marta
  • Fausther-Bovendo, Hughes
  • Pernas, María
  • Massanella, Marta|||0000-0002-3326-151X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • López-Galíndez, Cecilio|||0000-0002-2324-9584
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Debré, Patrice
  • Vieillard, Vincent
  • Blanco, Julià|||0000-0002-2225-0217
CD4 T-cell decay is variable among HIV-infected individuals. In exceptional cases, CD4 T-cell counts remain stable despite high plasma viremia. HIV envelope glycoprotein (Env) properties, namely tropism, fusion or the ability to induce the NK ligand NKp44L, or host factors that modulate Env cytopathic mechanisms may be modified in such situation. We identified untreated HIV-infected individuals showing non-cytopathic replication (VL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients

  • Aparicio Prats, Ester
  • Parera, Mariona|||0000-0002-0756-8307
  • Franco Cirera, Sandra|||0000-0003-4126-2202
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Tural Llacher, Maria Cristina|||0000-0001-8894-6113
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez, Miguel Angel
Recent genome-wide association studies report that the SNP rs8099917, located 8.9 kb upstream of the start codon of IL28B, is associated with both disease chronicity and therapeutic response to pegIFN-α and RBV in patients infected with genotype 1 HCV. To determine the effect of rs8099917 variation on the response of HCV to therapy, we genotyped this variant in a cohort of 160 HCV/HIV-1 coinfected patients in our clinic unit who received combined peg-IFN-α/RBV therapy. The rs8099917 T/G or G/G genotypes were observed in 56 patients (35%). Treatment failure occurred in 80% of G-allele carriers versus 48% of non-carriers (P<0.0001). This result reveals that the G allele was strongly associated with treatment failure in this patient cohort. Importantly, a highly significant association was found between the G-allele and response to therapy in HCV genotype 1-infected patients (P<0.0001) but not in HCV genotype 3-infected patients. Multivariate analysis (odds ratio; 95% confidence interval; P value) indicated that the rs8099917 TT genotype was a strong predictor of treatment success (5.83; 1.26-26.92; P = 0.021), independent of baseline plasma HCV-RNA load less than 500 000 IU/ml (4.85; 1.18-19.95; P = 0.025) and absence of advanced liver fibrosis (5.24; 1.20-22.91; P = 0.025). These results reveal the high prevalence of the rs8099917 G allele in HCV/HIV-1 coinfected patients as well as its strong association with treatment failure in HCV genotype 1-infected patients. rs8099917 SNP genotyping may be a valid pre-treatment predictor of which patients are likely to respond to treatment in this group of difficult-to-treat HCV/HIV-infected patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis

  • Jesson, Julie|||0000-0002-9461-2520
  • Crichton, Siobhan
  • Quartagno, Matteo
  • Yotebieng, Marcel
  • Abrams, Elaine J.
  • Chokephaibulkit, Kulkanya|||0000-0002-0140-4600
  • Le Coeur, Sophie
  • Aké-Assi, Marie-Hélène
  • Patel, Kunjal|||0000-0003-0002-681X
  • Pinto, Jorge
  • Paul, Mary
  • Vreeman, Rachel
  • Davies, Mary-Ann|||0000-0001-8496-6475
  • Ben-Farhat, Jihane
  • Van Dyke, Russell
  • Judd, Ali|||0000-0003-3176-5295
  • Mofenson, Lynne|||0000-0002-2818-9808
  • Vicari, Marissa
  • Seage, George
  • Bekker, Linda-Gail|||0000-0002-0755-4386
  • Essajee, Shaffiq
  • Gibb, Diana
  • Penazzato, Martina|||0000-0001-5485-8692
  • Collins, Intira Jeannie|||0000-0003-2132-6037
  • Wools-Kaloustian, Kara
  • Slogrove, Amy
  • Powis, Kate|||0000-0002-4478-4471
  • Williams, Paige
  • Matshaba, Mogomotsi
  • Thahane, Lineo
  • Nyasulu, Phoebe
  • Lukhele, Bhekumusa
  • Mwita, Lumumba
  • Kekitiinwa-Rukyalekere, Adeodata
  • Wanless, Sebastian
  • Goetghebuer, Tessa
  • Thorne, Claire
  • Warszawski, Josiane
  • Galli, Luisa|||0000-0002-7912-3366
  • van Rossum, Annemarie M. C.
  • Giaquinto, Carlo
  • Marczynska, Magdalena
  • Marques, Laura
  • Prata, Filipa
  • Ene, Luminita
  • Okhonskaya, Lyuba
  • Navarro, Maria Luisa
  • Frick, Antoinette
  • Naver, Lars
  • Kahlert, Christian|||0000-0002-0784-3276
  • Volokha, Alla|||0000-0003-3092-2228
  • Chappell, Elizabeth|||0000-0003-1053-6434
  • Pape, Jean William
  • Rouzier, Vanessa
  • Marcelin, Adias
  • Succi, Regina
  • Sohn, Annette H.|||0000-0002-0209-3285
  • Kariminia, Azar
  • Edmonds, Andrew
  • Lelo, Patricia
  • Lyamuya, Rita
  • Ogalo, Edith Apondi|||0000-0002-7968-9394
  • Odhiambo, Francesca Akoth
  • Haas, Andreas D.|||0000-0002-4849-181X
  • Bolton, Carolyn|||0000-0001-9103-7746
  • Muhairwe, Josephine
  • Tweya, Hannock
  • Sylla, Mariam
  • D'Almeida, Marceline
  • Renner, Lorna
  • Abzug, Mark J.
  • Oleske, James
  • Purswani, Murli
  • Teasdale, Chloe
  • Nuwagaba-Biribonwoha, Harriet|||0000-0001-5131-3371
  • Goodall, Ruth
  • Leroy, Valériane|||0000-0003-3542-8616
Adolescents living with HIV are subject to multiple co-morbidities, including growth retardation and immunodeficiency. We describe growth and CD4 evolution during adolescence using data from the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) global project. Data were collected between 1994 and 2015 from 11 CIPHER networks worldwide. Adolescents with perinatally acquired HIV infection (APH) who initiated antiretroviral therapy (ART) before age 10 years, with at least one height or CD4 count measurement while aged 10-17 years, were included. Growth was measured using height-for-age Z-scores (HAZ, stunting if <-2 SD, WHO growth charts). Linear mixed-effects models were used to study the evolution of each outcome between ages 10 and 17. For growth, sex-specific models with fractional polynomials were used to model non-linear relationships for age at ART initiation, HAZ at age 10 and time, defined as current age from 10 to 17 years of age. A total of 20,939 and 19,557 APH were included for the growth and CD4 analyses, respectively. Half were females, two-thirds lived in East and Southern Africa, and median age at ART initiation ranged from <3 years in North America and Europe to.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

  • Santos, José Ramón|||0000-0002-0886-7114
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Portilla, Joaquín|||0000-0002-3676-9511
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Vilchez, Helem|||0000-0002-4344-693X
  • Curran, Adrian|||0000-0002-1263-0814
  • Valcarce-Pardeiro, Nieves
  • Payeras, Antoni
  • Bernal, Enrique|||0000-0002-4041-0579
  • Montero-Alonso, Marta
  • Yzusqui, Miguel
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Videla, Sebastià
  • Moltó, José|||0000-0003-4564-1963
  • Paredes, Roger|||0000-0002-6553-691X
Suppressed patients with drug-resistant HIV-1 require effective and simple antiretroviral therapy to maintain treatment adherence and viral suppression. This randomized, open-label, noninferiority, multicenter pilot study involved HIV-infected adults who met the following criteria: confirmed HIV-1 RNA <50 copies/mL for ≥6 months preceding the study randomization, treatment with at least 3 antiretroviral drugs, and a history of drug resistance mutations against at least 2 antiretroviral classes but remaining fully susceptible to darunavir (DRV) and integrase inhibitors. Participants were randomized 1:1 to switch to dolutegravir (DTG; 50 mg once per day) plus DRV boosted with cobicistat (DRV/c; 800/150 mg once per day; 2D group) or continue with their baseline regimen (standard-of-care [SOC] group). The primary endpoint was the proportion of patients with HIV-1 RNA <50 copies/mL at week 48 relative to time to loss of virologic response, with a noninferiority margin set at -12.5%. Virologic failure was defined as confirmed HIV-1 RNA ≥50 copies/mL or a single determination of HIV-1 RNA.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Polyanionic N-donor ligands as chelating agents in transition metal complexes: synthesis, structural characterization and antiviral properties against HIV

  • García Gallego, Sandra|||0000-0001-6112-0450
  • Rodríguez Sánchez, Javier
  • Jiménez, José Luis
  • Cangiotti, Michela
  • Ottaviani, Maria Francesca
  • Muñoz Fernández, María Ángeles
  • Gómez Ramírez, Rafael|||0000-0001-6448-2414
  • Mata de la Mata, Francisco Javier de la|||0000-0003-0418-3935
We describe here the synthesis and characterization of new sulfonated and carboxylated-containing N-donor ligands [Na-4(edts)]center dot 4H(2)O (2), [Na-2(dmeddp)]center dot 2H(2)O (3) and [Na-4(edtp)]center dot H2O (4) (edts = ethylene-diamine-N,N,N',N'-tetraethylenesulfonate ion; dmeddp = dimethyl-ethylene-diamine-N,N,N',N'-tetra-3-propionate ion; edtp = ethylene-diamine-N,N,N',N'-tetra-3-propionate ion) and their corresponding metal (Ni, Co, Cu and Zn) complexes. Mainly, UV-Vis and a computer aided analysis of the EPR spectra provided information on the geometry and structure of the complexes in solution. Some of the metal complexes inhibit HIV replication when treating both pre- and post-infected PBMC cells, and hustle the inhibitory effect compared to the metal salts alone., Ministerio de Sanidad y Consumo, Red RIS, FPISE, MNT-ERA NET 2007, Fundación Caja Navarra, Comunidad de Madrid, Universidad de Alcalá, Instituto de Salud Carlos III
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Amphiphilic Cationic Carbosilane-PEG Dendrimers: Synthesis and Applications in Gene Therapy

  • Sánchez-Nieves Fernández, Javier|||0000-0003-0410-2285
  • Fransen, Peter
  • Pulido, Daniel
  • Llorente Heras, Raquel
  • Muñoz Fernández, María Ángeles
  • Albericio, Fernando
  • Royo, Miriam
  • Gómez Ramírez, Rafael|||0000-0001-6448-2414
  • Mata de la Mata, Francisco Javier de la|||0000-0003-0418-3935
Here we synthesized carbosilane, generation 1 to 3, and PEG-based dendrons functionalized at the periphery with NHBoc groups and at the focal point with azide and alkyne moieties, respectively. The coupling of these two types of dendrons via click chemistry led to the formation of new hybrid dendrimers with two distinct moieties, the hydrophobic carbosilane and the hydrophilic PEG-based dendron. The protected dendrimers were transformed into cationic ammonium dendrimers. These unique amphiphilic dendrimers were studied as vectors for gene therapy against HIV in peripheral blood mononuclear cells (PBMC) and their performance was compared with that of a PEG-free carbosilane dendrimer. The presence of the PEG moiety afforded lower toxicities and evidenced a weaker interaction between dendrimers and siRNA when compared to the homodendrimer analogous. Both features, lower toxicity and lower dendriplex strength, are key properties for use of these vectors as carriers of nucleic material., Comunidad de Madrid, Ministerio de Sanidad y Consumo, Ministerio de Economía y Empresa
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

In Vitro Studies of Water-Stable Cationic Carbosilane Dendrimers As Delivery Vehicles for Gene Therapy Against HIV and Hepatocarcinoma

  • Cuevas, Natividad de las
  • García Gallego, Sandra|||0000-0001-6112-0450
  • Rasines Moreno, Beatriz
  • Mata de la Mata, Francisco Javier de la|||0000-0003-0418-3935
  • González Guijarro, Luis Alberto|||0000-0003-4979-2136
  • Muñoz Fernández, María Ángeles
  • Gómez Ramírez, Rafael|||0000-0001-6448-2414
Here we present a synthetic procedure for water-stable carbosilane dendrimers containing ammonium groups at the periphery of type Gn-{[Si(CH2)3N+(Me)(Et)CH2CH2N+Me3]x (CF3SO3 -)y} which have been used as non-viral vectors for transfecting different types of nucleic acids against two different medical problems, HIV and hepatocarcinoma. These systems have shown to be non-toxic in both PBMC and HepG2 cell lines under the experimental conditions and are able to form nanoconjugates with nucleic acids perfectly stable over time and in a wide range of pH values, which leads to the conclusion that the interaction between dendrimer and nucleic acid is very strong. In addition, a high degree of transfection using these nanoconjugates has been observed, ranging from 70-90% depending on the generation and in the particular case of PBMC transfection with anti-HIV oligonucleotides. However, besides of the good properties shown by the dendrimers here prepared as transfecting agents, only moderate effect was observed in functional experiments for hepatocarcinoma, as a result of the strong interaction between dendrimer and nucleic acid. Nevertheless, it is important to mention that an IRS-4 knock-down of 40% in HepG2 achieves an analogous degree of cell sensitization to cancer treatment, which may represent a major advance in the hepatocarcinoma treatment when appropriate dendrimers as transfection agents are used., Ministerio de Sanidad y Consumo, Red RIS, Fundación Caja Navarra, Comunidad de Madrid, Instituto de Salud Carlos III